NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has announced that its Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus and other Ebola viruses is expected to commence soon in the Democratic Republic of Congo (DRC). The company has received regulatory approval from the local agency ACOREP and has appointed Professor Patrick Katoto as principal investigator. Preparatory activities, including staff training, are underway, and the NV-387 drug product is already available in the DRC, with first patient dosing anticipated within a few weeks, barring outbreak-related impediments.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. NanoViricides believes that oral delivery could offer significant advantages in resource-limited outbreak settings compared with treatments requiring infusions, which often demand specialized healthcare infrastructure and trained personnel. This could be particularly crucial in the DRC, where Ebola outbreaks have historically posed logistical challenges for intravenous therapies.
The company has engaged Om Sai Clinical Research Private Limited as the contract research organization for this Phase II trial, as well as for its planned Phase II trial of NV-387 Oral Gummies for the treatment of Mpox in the DRC. This dual use of the same drug candidate underscores the potential broad-spectrum utility of NV-387 against multiple viral threats, which could streamline regulatory pathways and manufacturing processes.
The significance of this trial extends beyond the immediate Ebola outbreak. If successful, NV-387 could become a critical tool in pandemic preparedness, particularly for viral hemorrhagic fevers that often emerge in regions with limited healthcare access. The oral formulation could enable earlier intervention and broader distribution, potentially reducing transmission and mortality. Moreover, the progress of NV-387 through clinical trials may bolster NanoViricides’ pipeline, which includes candidates for COVID-19, influenza, and other respiratory viruses, as well as mpox and measles.
However, the company acknowledges the inherent risks in drug development, including the lengthy and capital-intensive path to approval. There is no assurance that NV-387 will demonstrate sufficient efficacy and safety in clinical trials. Nevertheless, the initiation of this Phase II trial represents a meaningful step forward in addressing Ebola, a disease with high fatality rates and limited treatment options.
For more information on this announcement, the full press release can be viewed at https://ibn.fm/uWVTo. Additional updates on NanoViricides are available at https://ibn.fm/NNVC.
